Kalaris Therapeutics Under Investigation Over Board Conduct Before Restructuring
New York, Tuesday, 4 August 2026.
Abbott Cooper PLLC has launched an investigation into Kalaris Therapeutics board members regarding potential breaches of fiduciary duty toward long-term shareholders prior to major corporate restructuring.
Investigation into Fiduciary Duties
Abbott Cooper PLLC has formally initiated an investigation into potential breaches of fiduciary duty by the board of directors of Kalaris Therapeutics, Inc. [1]. Announced on August 3, 2026, the inquiry specifically scrutinizes actions taken prior to November 7, 2024 [1]. This date serves as a critical threshold for shareholders who acquired stock before major corporate restructuring activities commenced [1]. The core objective is to determine if directors acted in the best interest of shareholders during this pivotal period [1].
Shareholder Eligibility and Corporate History
Eligibility for this investigation targets stockholders who have continuously held shares since before the November 2024 cutoff [1]. Kalaris Therapeutics was previously known as AlloVir, Inc., trading under the ticker ALVR before transitioning to KLRS [1]. The firm is examining whether directors maintained their fiduciary responsibilities to these pre-merger shareholders during the corporate transition [1]. Such restructuring represents a significant event in the company’s financial timeline and requires careful oversight [1].
Legal Representation and Contact Information
Abbott Cooper PLLC handles these cases on a contingency fee basis, meaning there is no cost to stockholders unless a recovery is obtained [1]. Interested parties are encouraged to contact the firm to discuss legal rights without obligation [1]. The law firm is located in Stamford, Connecticut, and can be reached via their provided contact channels [1]. Contact information includes a physical address in Stamford and a dedicated phone line for inquiries [1].